IUBMB Life · Nov 17, 2026
Imatinib as a Modulator of Lung Mechanotransduction: Reverting the Fibrotic Feedback Loop
By Greco A, Tranchida N, Cordaro M et al.
Pulmonary fibrosis continues to pose a substantial clinical challenge, characterized by relentless progression, limited therapeutic avenues, and poor prognosis. This review provides a comprehensive overview of current insights into extracellular matrix remodeling, mechanotransduction pathways, and canonical signaling networks operating in the fibrotic lung, with emphasis on how mechanical cues are translated into enduring pro‐fibrotic gene expression programs. The involvement of the tyrosine kinase c‐abl is explored as a potential central mediator within fibrotic feedback mechanisms. Additionally, the interplay between aging, cellular senescence, and disease pathogenesis is discussed, focusing on the role of the senescence‐associated secretory phenotype (SASP) in fostering a persistent pro‐fibrotic microenvironment. Against this background, the therapeutic potential of imatinib is evaluated for its capacity to modulate c‐abl‐driven signaling and interrupt self‐sustaining fibrotic loops. Taken together, these observations point toward a conceptual model wherein targeting critical integrative signaling hubs may offer a promising approach to counter the self‐perpetuating nature of progressive fibrotic lung disease.